IL325945A - תרופות רדיואקטיביות המכוונות ל-psma לטיפול בסרטן - Google Patents
תרופות רדיואקטיביות המכוונות ל-psma לטיפול בסרטןInfo
- Publication number
- IL325945A IL325945A IL325945A IL32594526A IL325945A IL 325945 A IL325945 A IL 325945A IL 325945 A IL325945 A IL 325945A IL 32594526 A IL32594526 A IL 32594526A IL 325945 A IL325945 A IL 325945A
- Authority
- IL
- Israel
- Prior art keywords
- psma
- cancer
- treatment
- targeted radiopharmaceuticals
- radiopharmaceuticals
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dispersion Chemistry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363515943P | 2023-07-27 | 2023-07-27 | |
| PCT/CA2024/050996 WO2025019952A1 (en) | 2023-07-27 | 2024-07-26 | Psma-targeted radiopharmaceuticals for treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL325945A true IL325945A (he) | 2026-03-01 |
Family
ID=94373788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL325945A IL325945A (he) | 2023-07-27 | 2024-07-26 | תרופות רדיואקטיביות המכוונות ל-psma לטיפול בסרטן |
Country Status (10)
| Country | Link |
|---|---|
| KR (1) | KR20260043111A (he) |
| CN (1) | CN121752301A (he) |
| AR (1) | AR133391A1 (he) |
| AU (1) | AU2024298849A1 (he) |
| CO (1) | CO2026002011A2 (he) |
| DO (1) | DOP2025000324A (he) |
| IL (1) | IL325945A (he) |
| MX (1) | MX2026000917A (he) |
| TW (1) | TW202510848A (he) |
| WO (1) | WO2025019952A1 (he) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018108287A1 (en) * | 2016-12-15 | 2018-06-21 | The European Atomic Energy Community (Euratom), Represented By The European Commission | Treatment of pmsa expressing cancers |
| US11541134B1 (en) * | 2021-08-02 | 2023-01-03 | Rayzebio, Inc. | Stabilized compositions of radionuclides and uses thereof |
| CN118946371A (zh) * | 2022-01-28 | 2024-11-12 | 融合制药公司 | 靶向psma的放射性药物和检查点抑制剂的组合疗法 |
-
2024
- 2024-07-26 IL IL325945A patent/IL325945A/he unknown
- 2024-07-26 AU AU2024298849A patent/AU2024298849A1/en active Pending
- 2024-07-26 KR KR1020267005545A patent/KR20260043111A/ko active Pending
- 2024-07-26 CN CN202480048903.9A patent/CN121752301A/zh active Pending
- 2024-07-26 WO PCT/CA2024/050996 patent/WO2025019952A1/en active Pending
- 2024-07-29 AR ARP240101991A patent/AR133391A1/es unknown
- 2024-07-29 TW TW113128123A patent/TW202510848A/zh unknown
-
2025
- 2025-12-17 DO DO2025000324A patent/DOP2025000324A/es unknown
-
2026
- 2026-01-23 MX MX2026000917A patent/MX2026000917A/es unknown
- 2026-02-20 CO CONC2026/0002011A patent/CO2026002011A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20260043111A (ko) | 2026-03-31 |
| AU2024298849A1 (en) | 2026-01-15 |
| AR133391A1 (es) | 2025-09-24 |
| MX2026000917A (es) | 2026-03-02 |
| CN121752301A (zh) | 2026-03-27 |
| WO2025019952A1 (en) | 2025-01-30 |
| TW202510848A (zh) | 2025-03-16 |
| CO2026002011A2 (es) | 2026-03-05 |
| DOP2025000324A (es) | 2026-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3065771T3 (en) | Substituted oxoisoindoline compounds for the treatment of cancer | |
| IL307964A (he) | טיפול משולב לטיפול בסרטן | |
| IL316829A (he) | מעכבי מנין-mll לטיפול בסרטן | |
| IL289201A (he) | תרכובות לטיפול בסרטן | |
| RS67777B1 (sr) | Postupak tretiranja tumora | |
| GB202107994D0 (en) | Treatment of cancer | |
| IL305780A (he) | שיטות לטיפול בסרטן | |
| IL314687A (he) | טיפול בסרטן | |
| IL312155A (he) | שיטה לטיפול בסרטן | |
| CA3296090A1 (en) | Psma-targeted radiopharmaceuticals for treatment of cancer | |
| AU2024298849A1 (en) | Psma-targeted radiopharmaceuticals for treatment of cancer | |
| EP4452946A4 (en) | CONNECTIONS FOR THE TREATMENT OF CANCER | |
| GB202311976D0 (en) | Treatment of cancer | |
| GB202218181D0 (en) | Treatment of cancer | |
| IL272390A (he) | שיטות לטיפול בסרטן | |
| GB202201803D0 (en) | Treatment of Cancer | |
| GB201918815D0 (en) | Treatment of cancer | |
| IL312899A (he) | טיפול משולב לטיפול בסרטן | |
| IL300106A (he) | תרפיית שילוב לטיפול בסרטן | |
| GB202508597D0 (en) | Compounds for the treatment of cancer | |
| GB202018062D0 (en) | Treatment of cancer | |
| GB202008037D0 (en) | Treatment of cancer | |
| IL320482A (he) | טיפול משולב לטיפול בסרטן | |
| IL315444A (he) | מערכת ביטוי לטיפול בסרטן | |
| GB202013074D0 (en) | Method of treatment for cancer |